Overview
Precision Instruments

CellSeed Inc.

CellSeed is a Japanese biotechnology company pioneering 'Cell Sheet Engineering,' a proprietary regenerative medicine platform that cultivates cell sheets using temperature-responsive cell culture instruments to treat diseases unaddressable by conventional therapies. The company operates two business segments: a Regenerative Medicine Support Business, which develops, manufactures, and sells temperature-responsive cell culture instruments and provides contract R&D/manufacturing services; and a Cell Sheet Regenerative Medicine Business, focused on the development and commercialization of cell sheet-based therapeutic products. CellSeed aims to be the first to commercialize a cell sheet regenerative medicine product and to expand this Japan-originated technology globally.

Market Cap
¥7.43B
US$47.4M
EV
¥5.73B
US$36.6M
Stock¥189▼-1.56%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
—
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
4.2
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-77.3%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
7.43BUS$47.4MMarket Cap0.12BUS$0.75M+ Debt1.79BUS$11.4M− Cash0.02BUS$0.14M− Inv. Sec.5.73BUS$36.6MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.16US$1.03M'21/120.13US$0.80M'22/120.19US$1.21M'23/120.19US$1.23M'24/120.08US$0.53M'25/12
EBITDA 5Y (¥B)
-0.86-US$5.49M'21/12-0.74-US$4.69M'22/12-0.69-US$4.39M'23/12
Net Income 5Y (¥B)
-0.91-US$5.83M'21/12-0.76-US$4.84M'22/12-0.85-US$5.40M'23/12-0.86-US$5.48M'24/12-1.10-US$7.04M'25/12
Capital Structure
94%
EquityD/E 0.07xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
0.85US$5.40M0.16US$1.02M'21/121.07US$6.84M0.16US$1.01M'22/122.18US$13.9M0.15US$0.96M'23/122.15US$13.7M0.14US$0.92M'24/121.34US$8.55M0.13US$0.85M'25/12
Shareholders
Top 10 hold 8.1%
1
Rakuten Securities, Inc.
1.40%
2
Ueda Yagi Tanshi Co., Ltd.
1.34%
3
SBI SECURITIES Co., Ltd.
1.12%
4
Nissin Seiki Co., Ltd.
0.96%
5
Nomura Securities Co., Ltd.
0.91%
6
JPMorgan Securities Japan Co., Ltd.
0.72%
7
Hiroyuki NISHIDA
0.50%
8
Atsushi SAHARA
0.38%
9
Dai Nippon Printing Co.,Ltd.
0.37%
10
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M ONE CHURCHILL PLACE, LONDON, E14 5HP UNITED KINGDOLSCB RD (Standing Proxy: MUFG Bank, Ltd.)
0.35%
Management
6 officers
Setsuko HASHIMOTO
Representative Director, President
Apr 1984 Joined Hoechst Japan Ltd. Apr 1991 Joined Pharmacia Biotech K.K. Jul 1998 General Manager, Marketing and Development Departments, Biacore K.K. Jul 2008 Founded Bio Business Bridge Co., Ltd.; Representative Director, President Feb 2009 Senior Investment Officer, Investment Department, Embassy of Sweden Mar 2014 Director and Executive Vice President, the Company Jun 2014 Representative Director, President, the Company (current) Nov 2015 Director, Bio Business Bridge Co., Ltd. (current)
1953-08-15
Toshihiro MAEDA
Director, Head of Development Strategy Division
Apr 1980 Joined The Chemo-Sero-Therapeutic Research Institute (currently General Incorporated Foundation, Chemo-Sero-Therapeutic Research Institute) Mar 1983 Visiting Researcher, Harvard Medical School (concurrent) Mar 1985 Received Ph.D. in Science, Kyushu University Apr 1992 General Manager, Pharmaceutical Development Department, the same organization Apr 2000 General Manager, Business Development Department and Head, Research Planning Office, the same organization Apr 2011 Visiting Professor, Graduate School of Pharmaceutical Sciences, Sojo University (concurrent) Jul 2014 Joined GeneTechno Science Co., Ltd.; General Manager, Business Development Department Oct 2017 Joined the Company; Head, Overseas Business Office Apr 2021 Head, Development Strategy Office, the Company Mar 2025 Director, Head of Development Strategy Office, the Company May 2025 Director, Head of Development Strategy Division, the Company (current)
1955-11-03
Keiichiro NAKAOKA
Director, Head of Corporate Management Division
Feb 2000 Joined Kitasato Pharmaceutical Industry Co., Ltd. Apr 2005 Chief, General Affairs Section, General Affairs Department, Administration Division, the same company Apr 2011 Assistant Manager, Accounting Section, Administration Division, the same company Aug 2016 Assistant Manager, Accounting and General Affairs Sections, Administration Division, the same company Oct 2019 Joined the Company; Manager, Human Resources and General Affairs Department Oct 2022 General Manager, General Affairs and Legal Department, the Company Mar 2025 Director, General Manager, General Affairs and Legal Department, the Company May 2025 Director, Head of Corporate Management Division, the Company (current)
1975-12-01
Kenji OEDA
Director (Audit and Supervisory Committee Member)
Apr 1982 Joined Sumitomo Chemical Co., Ltd. Oct 1990 Senior Researcher, Biotechnology Research Laboratory, the same company Jan 2007 Deputy Director-General for Science and Technology Policy, Cabinet Office, Government of Japan Jan 2010 Fellow, Sumitomo Chemical Co., Ltd. Apr 2011 Executive Director, RIKEN Apr 2015 Advisor, RIKEN Jul 2015 Director, Sumika Technical Information Center Co., Ltd. Mar 2017 Director, the Company Jun 2018 Managing Director, The Engineering Academy of Japan Jun 2020 Life Fellow, The Engineering Academy of Japan (current) Dec 2021 Project Professor, Office of Industry-Academia-Government Collaboration, Kyoto University (current) Director (Audit and Supervisory Committee Member), the Company (current) Mar 2023 Outside Corporate Auditor, Symbiobe Inc. Aug 2024 (current)
1951-09-10
Sachiko ENDO
Director (Audit and Supervisory Committee Member)
Apr 1976 Joined Fujitsu Limited Oct 1979 Joined Hatada Tax Accountant Office Apr 1997 Joined Torikai Sogo Law Office Jan 1998 Mediation Committee Member, Tokyo Family Court (current) Apr 2003 Joined Ogawa Sogo Law Office Apr 2009 Established Veritas Law Office; Representative Attorney (current) Dec 2016 Director (Audit and Supervisory Committee Member), Seiyu Kogyo Co., Ltd. (current) Apr 2021 Member, Tokyo Metropolitan Environmental Council (current) May 2021 Outside Director, Nihon Zetoc Co., Ltd. (current) Mar 2023 Director (Audit and Supervisory Committee Member), the Company (current)
1954-02-17
Tetsuomi MANO
Director (Audit and Supervisory Committee Member)
Oct 2002 Joined Shin Nihon & Co. (currently EY Shin Nihon LLC) Feb 2003 Joined Azsa & Co. (currently Azsa LLC) Jun 2006 Registered as Certified Public Accountant Sep 2006 Opened Mano Certified Public Accountant Office (current) Jan 2014 Registered as Certified Tax Accountant Oct 2015 Director, Deep Impact Co., Ltd. (current) Mar 2025 Assumed office as Director (Audit and Supervisory Committee Member), the Company (current)
1979-06-22
Large Shareholding Reports
Barclays Bank PLC
2026-09-25
8.86%→9.70%
Barclays Bank PLC
2026-06-25
9.34%→10.20%
Barclays Bank PLC
2026-06-24
9.34%→9.24%
Barclays Bank PLC
2026-06-22
12.64%→9.34%
Barclays Bank PLC
2026-03-31
13.92%→12.64%
Barclays Bank PLC
2026-03-04
14.96%→13.92%
Barclays Bank PLC
2026-02-27
16.14%→14.96%
Barclays Bank PLC
2026-02-24
17.77%→16.14%
Barclays Bank PLC
2026-01-29
15.68%→17.77%
Barclays Bank PLC
2026-01-28
18.29%→15.68%
Barclays Bank PLC
2026-01-22
20.10%→18.29%
Barclays Bank PLC
2026-01-13
21.11%→18.19%
Barclays Bank PLC
2026-01-13
18.19%→20.10%
Barclays Bank PLC
2026-01-06
19.40%→21.11%
Barclays Bank PLC
2026-01-05
22.08%→19.40%
Barclays Bank PLC
2025-12-19
19.82%→22.08%
Barclays Bank PLC
2025-12-16
22.29%→19.82%
Barclays Bank PLC
2025-12-15
22.29%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-09-25
Large Shareholding Report
EDINET
2026-08-14
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-13
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-06-25
Large Shareholding Report
EDINET
2026-06-24
Large Shareholding Report
EDINET
2026-06-22
Large Shareholding Report
TDnet
2026-05-13
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-31
Large Shareholding Report
EDINET
2026-03-26
Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2026-03-04
Large Shareholding Report
EDINET
2026-02-27
Large Shareholding Report
EDINET
2026-02-24
Large Shareholding Report
EDINET
2026-01-29
Large Shareholding Report
EDINET
2026-01-28
Large Shareholding Report
EDINET
2026-01-22
Large Shareholding Report
EDINET
2026-01-13
Large Shareholding Report
EDINET
2026-01-13
Large Shareholding Report
EDINET
2026-01-06
Large Shareholding Report
EDINET
2026-01-05
Large Shareholding Report
EDINET
2025-12-19
Large Shareholding Report
EDINET
2025-12-16
Large Shareholding Report
EDINET
2025-12-15
Large Shareholding Report
EDINET
2025-11-20
Securities Registration Statement
TDnet
2025-11-13
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-14
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-13
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-26
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-14
Semi-Annual Securities Report
Period: Jan 2024 – Jun 2024
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-28
Annual Securities Report
Period: Jan 2023 – Dec 2023
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →